SLE with Severe Autoimmune Thrombocytopenia: What to Do When Maintenance Therapy Fails to Sustain Platelet Count

This protocol targets a specific escalation point in systemic lupus erythematosus: patients with severe autoimmune thrombocytopenia whose platelet count remains below 20,000–30,000/mm³ despite maintenance therapy.

Clinical Scenario

Systemic lupus erythematosus with severe autoimmune thrombocytopenia. A platelet count below 20,000–30,000/mm³ represents the threshold at which active intervention is indicated.

Prior Treatment Line — Failure Condition

This protocol applies after maintenance therapy with rituximab, azathioprine, mycophenolate, or cyclosporine has failed to achieve or sustain a platelet count above 30,000/mm³.

Next-Line Approach (Partial Overview)

The next-line strategy centres on thrombopoietin receptor agonists. The complete evidence-based regimen is detailed in the full protocol.

Treatment Goal

Sustained platelet count above 30,000/mm³.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2023-224762

For acute treatment of severe autoimmune thrombocytopenia, high-dose glucocorticoids (including pulses of intravenous methylprednisolone) (4/C), with or without intravenous immunoglobulin G (4/C), and/or rituximab (2b/B), and/or high-dose intravenous cyclophosphamide (4/C), followed by maintenance therapy with rituximab (2b/B), azathioprine (2b/C), mycophenolate (2b/C), or cyclosporine (4/C) should be considered.

A platelet number of 20–30 000/mm³ is typically used as the cut-off, below which therapy is indicated.

In cases refractory to these drugs, thrombopoietin receptor (TPO) agonists and splenectomy are options; although the two modalities have not been formally compared in SLE and data mainly come from observational studies, it seems reasonable to use TPO agonists prior to splenectomy, given the possible complications and long-term sequelae of the latter.

View source ↗